Daiwa Capital Markets assumed coverage on shares of Legend Biotech (NASDAQ:LEGN – Get Rating) in a report published on Monday, The Fly reports. The firm issued a buy rating on the stock.
Several other analysts also recently issued reports on LEGN. BMO Capital Markets upped their price objective on shares of Legend Biotech from $79.00 to $90.00 in a report on Tuesday, April 25th. HC Wainwright raised their price objective on shares of Legend Biotech from $66.00 to $77.00 and gave the stock a buy rating in a report on Thursday, April 20th. Barclays lifted their target price on shares of Legend Biotech from $65.00 to $90.00 in a research report on Friday, May 19th. Morgan Stanley increased their price target on shares of Legend Biotech from $60.00 to $65.00 and gave the stock an overweight rating in a research report on Tuesday, January 24th. Finally, BTIG Research lifted their price objective on Legend Biotech from $75.00 to $85.00 and gave the company a buy rating in a report on Thursday, April 20th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $77.40.
Legend Biotech Stock Down 4.2 %
LEGN opened at $63.28 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.79 and a current ratio of 3.84. The business has a 50 day moving average price of $59.13 and a 200 day moving average price of $53.27. Legend Biotech has a twelve month low of $37.30 and a twelve month high of $73.30.
Hedge Funds Weigh In On Legend Biotech
Legend Biotech Company Profile
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma.
- Get a free copy of the StockNews.com research report on Legend Biotech (LEGN)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.